Skip to content
10-Q

Quarterly Report

Keenova Therapeutics plc

0001628280-26-034209

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 39.58M sh
Shares Diluted Q1 2026 · Mar 31, 2026 39.6M sh
Shares Diluted Q1 2026 · Mar 28, 2025 19.7M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $1.9M
Stock Repurchased Q1 2026 · Mar 28, 2025 $1.9M
Capex Q1 2026 · Mar 31, 2026 $10.4M
Capex restated Q1 2026 · Mar 28, 2025 $10.6M
Short Term Debt Q1 2026 · Mar 31, 2026 $15M
Short Term Debt Q1 2026 · Dec 31, 2025 $15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $824.9M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $812.8M
Cash And Equivalents restated Q1 2026 · Mar 28, 2025 $348.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.96B
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.07B
Stockholders Equity Q1 2026 · Mar 28, 2025 $1.63B
Stockholders Equity Q1 2026 · Dec 27, 2024 $1.65B
Current Liabilities Q1 2026 · Mar 31, 2026 $638.3M
Current Liabilities Q1 2026 · Dec 31, 2025 $672.1M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.52B
Total Liabilities Q1 2026 · Dec 31, 2025 $3.56B
Current Assets Q1 2026 · Mar 31, 2026 $1.92B
Current Assets Q1 2026 · Dec 31, 2025 $1.92B
Total Assets Q1 2026 · Mar 31, 2026 $5.47B
Total Assets Q1 2026 · Dec 31, 2025 $5.63B
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.87
Eps Diluted Q1 2026 · Mar 28, 2025 −$1.41
Eps Basic Q1 2026 · Mar 31, 2026 −$2.87
Eps Basic Q1 2026 · Mar 28, 2025 −$1.41
Sga Expense Q1 2026 · Mar 31, 2026 $210.6M
Sga Expense restated Q1 2026 · Mar 28, 2025 $114.9M
Rd Expense Q1 2026 · Mar 31, 2026 $23.2M
Rd Expense restated Q1 2026 · Mar 28, 2025 $15.3M
Net Income Q1 2026 · Mar 31, 2026 −$113.5M
Net Income Q1 2026 · Mar 28, 2025 −$27.7M
Operating Income Q1 2026 · Mar 31, 2026 −$67M
Operating Income restated Q1 2026 · Mar 28, 2025 −$36.6M
Gross Profit Q1 2026 · Mar 31, 2026 $186.6M
Gross Profit restated Q1 2026 · Mar 28, 2025 $112.1M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $281.7M
Cost Of Revenue restated Q1 2026 · Mar 28, 2025 $95.1M
Revenue Q1 2026 · Mar 31, 2026 $468.3M
Revenue restated Q1 2026 · Mar 28, 2025 $207.2M